A new PET probe, 18F-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine

Youn, Hyewon; Jeong, Jae Min; Chung, June-Key

doi:10.1007/s00259-010-1601-3

Cited by 12 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers from the same institution also showed that 18 F-TFB was effective as a NIS probe in the NIStransfected colon carcinoma cell line HCT116 (15). However, as pointed out by Youn et al (16), specific activities achieved by the reported method are substantially lower than those typically required for receptormediated radiopharmaceuticals (;30 GBq/mmol). In addition to this, a higher specific activity of 18 F-TFB (.1 GBq/mmol) is desired to avoid pharmacologic effects of administered TFB on iodine uptake in the thyroid (14).…”

mentioning

confidence: 86%

Synthesis of ¹⁸F-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model

et al. 2016

View full text Add to dashboard Cite

mentioning

confidence: 86%

Synthesis of ¹⁸F-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model

et al. 2016

View full text Add to dashboard Cite

“…As a reporter gene, it allows non-invasive imaging of tumoral MSC recruitment and biodistribution as well as duration and level of NIS transgene expression by 99m Tc-/ 123 I-scintigraphy, 123 I-SPECT (single photon emission computed tomography) or 124 I-/ 18 F-tetrafluoroborate-PET (positron emission tomography) and thus exact dosimetric calculations before the application of therapeutic radionuclides such as 131 I or 188 Re [16–18]. …”

Section: Introductionmentioning

confidence: 99%

Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery

et al. 2016

View full text Add to dashboard Cite

Adoptively transferred mesenchymal stem cells (MSCs) home to solid tumors. Biologic features within the tumor environment can be used to selectively activate transgenes in engineered MSCs after tumor invasion. One of the characteristic features of solid tumors is hypoxia. We evaluated a hypoxia-based imaging and therapy strategy to target expression of the sodium iodide symporter (NIS) gene to experimental hepatocellular carcinoma (HCC) delivered by MSCs.MSCs engineered to express transgenes driven by a hypoxia-responsive promoter showed robust transgene induction under hypoxia as demonstrated by mCherry expression in tumor cell spheroid models, or radioiodide uptake using NIS. Subcutaneous and orthotopic HCC xenograft mouse models revealed significant levels of perchlorate-sensitive NIS-mediated tumoral radioiodide accumulation by tumor-recruited MSCs using 123I-scintigraphy or 124I-positron emission tomography. Functional NIS expression was further confirmed by ex vivo 123I-biodistribution analysis. Administration of a therapeutic dose of 131I in mice treated with NIS-transfected MSCs resulted in delayed tumor growth and reduced tumor perfusion, as shown by contrast-enhanced sonography, and significantly prolonged survival of mice bearing orthotopic HCC tumors. Interestingly, radioiodide uptake into subcutaneous tumors was not sufficient to induce therapeutic effects. Our results demonstrate the potential of using tumor hypoxia-based approaches to drive radioiodide therapy in non-thyroidal tumors.

show abstract

“…Thus, cells were transfected with the NIS gene, most often the human gene (hNIS), injected and imaged by SPECT using a variety of radioactive tracers including iodine-123 (sodium iodide) and technetium-99m (sodium pertechnetate) in a variety of animal models (28). NIS may also be used for PET with iodine-124 or 18 F-tetrafluoroborate (29,30). This approach was used recently to label tumor cells in vivo (31) and to monitor dendritic cell traffic from the skin to lymph nodes (32).…”

Section: Radioactive Imagingmentioning

confidence: 99%

Cell Tracking in Cancer Immunotherapy

et al. 2020

View full text Add to dashboard Cite

The impressive development of cancer immunotherapy in the last few years originates from a more precise understanding of control mechanisms in the immune system leading to the discovery of new targets and new therapeutic tools. Since different stages of disease progression elicit different local and systemic inflammatory responses, the ability to longitudinally interrogate the migration and expansion of immune cells throughout the whole body will greatly facilitate disease characterization and guide selection of appropriate treatment regiments. While using radiolabeled white blood cells to detect inflammatory lesions has been a classical nuclear medicine technique for years, new non-invasive methods for monitoring the distribution and migration of biologically active cells in living organisms have emerged. They are designed to improve detection sensitivity and allow for a better preservation of cell activity and integrity. These methods include the monitoring of therapeutic cells but also of all cells related to a specific disease or therapeutic approach. Labeling of therapeutic cells for imaging may be performed in vitro, with some limitations on sensitivity and duration of observation. Alternatively, in vivo cell tracking may be performed by genetically engineering cells or mice so that may be revealed through imaging. In addition, SPECT or PET imaging based on monoclonal antibodies has been used to detect tumors in the human body for years. They may be used to detect and quantify the presence of specific cells within cancer lesions. These methods have been the object of several recent reviews that have concentrated on technical aspects, stressing the differences between direct and indirect labeling. They are briefly described here by distinguishing ex vivo (labeling cells with paramagnetic, radioactive, or fluorescent tracers) and in vivo (in vivo capture of injected radioactive, fluorescent or luminescent tracers, or by using labeled antibodies, ligands, or pre-targeted clickable substrates) imaging methods. This review focuses on cell tracking in specific therapeutic applications, namely cell therapy, and particularly CAR (Chimeric Antigen Receptor) T-cell therapy, which is a fast-growing research field with various therapeutic indications. The potential impact of imaging on the progress of these new therapeutic modalities is discussed.

show abstract

A new PET probe, 18F-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine

Cited by 12 publications

References 15 publications

Synthesis of ¹⁸F-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model

Synthesis of ¹⁸F-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model

Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery

Cell Tracking in Cancer Immunotherapy

Contact Info

Product

Resources

About

A new PET probe, 18F-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine

Cited by 12 publications

References 15 publications

Synthesis of 18F-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model

Synthesis of 18F-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model

Hypoxia-targeted 131I therapy of hepatocellular cancer after systemic mesenchymal stem cell-mediated sodium iodide symporter gene delivery

Cell Tracking in Cancer Immunotherapy

Contact Info

Product

Resources

About

Synthesis of ¹⁸F-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model

Synthesis of ¹⁸F-Tetrafluoroborate via Radiofluorination of Boron Trifluoride and Evaluation in a Murine C6-Glioma Tumor Model